← All trials
NCT06732960
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 21, 2024
- Primary completion
- Dec 31, 2024
- Completion date
- Jan 31, 2025
- First posted
- Dec 13, 2024
- Last posted
- Dec 13, 2024
- Enrollment
- 50
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.Lead sponsor
- Jinan UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Capital Medical UniversityCollaborator
- Jiao Tong UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.